Indo-Bangla Pharmaceuticals (DHA:IBP) EV-to-EBIT: (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT19.30
View Full Analysis

What is Indo-Bangla Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Indo-Bangla Pharmaceuticals's Enterprise Value is BDT0.00 Mil. Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Indo-Bangla Pharmaceuticals's EV-to-EBIT at this moment.

The historical rank and industry rank for Indo-Bangla Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

DHA:IBP's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.42
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Indo-Bangla Pharmaceuticals's Enterprise Value for the quarter that ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Indo-Bangla Pharmaceuticals's Earnings Yield (Joel Greenblatt) % at this moment.

Indo-Bangla Pharmaceuticals  (DHA:IBP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Indo-Bangla Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 ) =EBIT / Enterprise Value (Q: . 20 )
=/
= %

Indo-Bangla Pharmaceuticals EV-to-EBIT Related Terms

Indo-Bangla Pharmaceuticals EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals EV-to-EBIT Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
EV-to-EBIT

Indo-Bangla Pharmaceuticals Semi-Annual Data
EV-to-EBIT

DHA:IBP vs : EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indo-Bangla Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Indo-Bangla Pharmaceuticals's EV-to-EBIT falls into.


DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals EV-to-EBIT Calculation

Indo-Bangla Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/
=

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT19.30
Price